India seeks to boost drug exports to semi regulated markets in Africa, Latin America, Southeast Asia
India is seeking to boost drugs exports to semi-regulated markets in Africa, Latin America, and Southeast Asia in a bid to reduce its reliance on the United States. The move is driven by concerns over potential U.S. tariff risks, officials from a government-backed trade body said on Thursday. While Indian pharmaceutical exports are currently exempt from President Donald Trump's tariffs of up to 50%, growing uncertainty and tensions between the countries have kept the industry cautious, Reuters reported. Referring to the U.S. tariffs, Pharmexcil Chairman Namit Joshi said,"It is a matter of concern for us." The Pharmaceuticals Export Promotion Council of India (Pharmexcil) also plans to push for sales of finished goods to China to bridge the trade deficit, the officials said. The Indian industry imports more than 60% of its raw materials and active pharmaceutical ingredients from China. In addition to targeting semi-regulated markets, India is also planning to boost its pharmaceutical exports to Russia, Brazil, and the Netherlands
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!